Details
Stereochemistry | RACEMIC |
Molecular Formula | C12H18Cl2N2O |
Molecular Weight | 277.1905 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(c1cc(c(c(c1)Cl)N)Cl)O
InChI
InChIKey=STJMRWALKKWQGH-UHFFFAOYSA-N
InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3
Molecular Formula | C12H18Cl2N2O |
Molecular Weight | 277.1905 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.deadiversion.usdoj.gov/drug_chem_info/clenbuterol.pdf
Curator's Comment:: description was created based on several sources, including
https://www.deadiversion.usdoj.gov/drug_chem_info/clenbuterol.pdf
Clenbuterol is agonist of beta2 adrenergic receptor. In some countries it is used as bronchodilator for treatment of asthma, but is not approved in USA. The drug is abused by bodybuilders and athletes for its ability to increase lean muscle mass and to reduce body fat. In 1998 FDA approved the clenbuterol-based Ventipulmin Syrup as a prescription-only drug for treatment of airway obstruction in horses.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19245211 |
570.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.rlsnet.ru/tn_index_id_1750.htm |
Primary | SPIROPENT Approved UseTreatment of asthma, chroncic obstructive bronchitis, emphysema and other diseases. |
||
Primary | CLENBUTEROL Approved UseTreatment of asthma, chroncic obstructive bronchitis, emphysema and other diseases. |
PubMed
Title | Date | PubMed |
---|---|---|
[Novel quantitative assessment of the tremorogenic effects of the beta 2-mimetics clenbuterol and salbutamol after oral administration]. | 1985 |
|
Clenbuterol-induced tardive dyskinesia. | 1991 Oct |
|
Is the "atypical" beta-receptor in the rat stomach fundus the rat beta 3 receptor? | 1995 Jan |
|
Early alterations of polyamine metabolism induced after acute administration of clenbuterol in mouse heart. | 1999 |
|
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors. | 2000 Jun |
|
[A case of immotile-dyskinetic cilia syndrome responding to clenbuterol hydrochloride and azithromycin]. | 2002 Jul |
|
Role of myometrial activity in sperm transport through the genital tract and in fertilization in sows. | 2002 May |
|
Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. | 2004 Jun 25 |
|
Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. | 2004 Mar |
|
Dobutamine inhibits phorbol-myristate-acetate-induced activation of nuclear factor-kappaB in human T lymphocytes in vitro. | 2004 Nov |
|
Dose-dependent apoptotic and necrotic myocyte death induced by the beta2-adrenergic receptor agonist, clenbuterol. | 2005 Dec |
|
[Resolution of clenbuterol hydrochloride enantiomers by thin-layer chromatography on silica gel impregnated with beta-cyclodextrin]. | 2005 Jul |
|
Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. | 2005 Mar 1 |
|
Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. | 2006 Apr |
|
[Use of ultrasensitive time-resolved fluoroimmunoassay for rapid detection of clenbuterol hydrochloride in urine]. | 2006 Nov |
|
An increase in murine skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) mRNA in response to exercise is mediated by beta-adrenergic receptor activation. | 2007 Jul |
|
Pulmonary edema after electroconvulsive therapy in a patient treated for long-standing asthma with a beta2 stimulant. | 2007 Mar |
|
Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and beta2-adrenoceptor mechanisms. | 2008 Oct |
|
Accumulation of the beta(2)-adrenergic agonist clenbuterol in mouse dark hair. | 2009 Nov |
|
Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis. | 2010 Apr |
|
Blocking beta2-adrenergic receptor attenuates acute stress-induced amyloid beta peptides production. | 2010 Mar 4 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rlsnet.ru/tn_index_id_1750.htm
For treatmen of airways obstruction the clenbuterol is administered orally, 15ml of syrop 2-3 times a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2993621
Affinity towards beta2 adrenergic receptors was measured using the recombinant receptor expressed in Sf-9 cells. Cell membrane homogenates were incubated with 0.15 nM of radioligand [3H]CGP1217 in the absence of presence of the clenbuterol. Following incubation, the samples were filtered rapidly under vacuum through through glass fiber filters, the filters were dried, and counted for radioactivity in a scintillation counter. Clenbuterol was binding to beta2 receptor with Ki of 0.58 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:55:18 UTC 2021
by
admin
on
Fri Jun 25 21:55:18 UTC 2021
|
Record UNII |
XTZ6AXU7KN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR03CC13
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
WHO-VATC |
QR03AC14
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
WHO-VATC |
QR03CC90
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
WHO-ATC |
R03CC13
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
CFR |
21 CFR 530.41
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
CFR |
21 CFR 520.452
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
FDA ORPHAN DRUG |
451614
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
FDA ORPHAN DRUG |
546316
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
WHO-ATC |
R03CC63
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
WHO-ATC |
R03AC14
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
FDA ORPHAN DRUG |
653918
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
WHO-VATC |
QG02CA91
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
673
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
SUB06651MIG
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
37148-27-9
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
D002976
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
XTZ6AXU7KN
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
37148-27-9
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
2783
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
3264
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
CLENBUTEROL
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
DB01407
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
2580
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | RxNorm | ||
|
M3615
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | Merck Index | ||
|
253-366-0
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
CHEMBL49080
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY | |||
|
C65335
Created by
admin on Fri Jun 25 21:55:18 UTC 2021 , Edited by admin on Fri Jun 25 21:55:18 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |